This study is a prospective observational study in which a female patient who received IV Artesunate while pregnant can volunteer to provide information about her pregnancy and the outcome of her pregnancy. Information will be collected from patient's provider, the patient's obstetrician, the child's pediatrician, or other relevant healthcare provider.
Pregnant women or physicians treating pregnant women with severe malaria with IV Artesunate will become aware of the Pregnancy Registry via the product label, the Amivas Inc. website, or her physician. By calling 1-855-526-4827 (1-855-5AMIVAS) or contacting www.amivas.com/our-products, the patient or physician will be connected to the Pregnancy Registry Call Center. In France, the Collaborating-Investigators conducting the ARTEMUM observatory study have a wide information campaign among obstetrical wards, neonatal wards, Infectious Diseases wards, intensive care units (ICU), and parasitology hospital laboratories, through expert networks of infectious diseases specialists, obstetricians and pediatricians in University hospitals from the Paris Area and suburbs that concentrate 50-55% of malaria cases in France. They also collaborate with the National Research Center (NRC) for malaria and will capture voluntary reports by clinicians and microbiologists in the NRC network. When contact is made to the call center, a trained staff member will acquaint the patient or treating physician with the goals and procedures of the study. If the patient agrees to participate in the study over the telephone, the patient's verbal consent will be documented, and the patient will be sent the study Consent Form that includes the consent for the patient's physician/obstetrician and the child's pediatrician to release medical information via email. If a physician is contacting the Call Center, s/he may be provided with this form to review, and the physician will be directed to ask the patient to telephone the Call Center to provide consent. With the patient's consent, the patient's physician/obstetrician will be contacted by a Call Center staff member and will be interviewed by a trained call center healthcare professional/pharmacist for information about the patient including demographics, malaria history, history of treatment, and initial pregnancy data. The Call Center will contact the patient's physicians (including obstetrician and infant's pediatrician, as appropriate) each trimester until delivery, and also at birth and 1 year after birth, to collect data on maternal adverse events (AEs), pregnancy outcome, fetal outcome, and infant outcome. Patients consented in France under the ARTEMUM study will undergo the consent process by the treating Physician. Anonymized data will be prospectively collected by a research technician under the supervision of a local manager in France. Data collected by the call center will be sent to the Coordinating Center on a monthly basis for review and tracking of participants, then annually for inclusion in the interim or final report. Data collected as part of the ARTEMUM study will be provided in aggregate as summary tables to be included in the annual report.
Study Type
OBSERVATIONAL
Enrollment
25
4C Pharma Solutions
Piscataway, New Jersey, United States
RECRUITINGNumber of pregnant females with high blood pressure
Number of pregnant females with high blood pressure reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with severe nausea
Number of pregnant females with severe nausea reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with vomiting
Number of pregnant females with vomiting reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with dehydration
Number of pregnant females with dehydration reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with diabetes (newly occurring)
Number of pregnant females with diabetes (newly occurring) reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with obesity/marked weight gain
Number of pregnant females with obesity/marked weight gain reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with anemia (newly occurring)
Number of pregnant females with anemia (newly occurring) reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with kidney or bladder infections
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of pregnant females with kidney or bladder infections reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with vaginal bleeding
Number of pregnant females with vaginal bleeding reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with abruptio placenta
Number of pregnant females with abruptio placenta reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with placenta previa
Number of pregnant females with placenta previa reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with premature rupture of membranes
Number of pregnant females with premature rupture of membranes reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with preterm labor
Number of pregnant females with preterm labor reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with ectopic pregnancy
Number of pregnant females with ectopic pregnancy reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with molar pregnancy
Number of pregnant females with molar pregnancy reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females who died
Number of pregnant females who died reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with spontaneous abortions/miscarriage
Number of pregnant females with spontaneous abortions/miscarriage reported in medical record
Time frame: Up to 20 weeks
Number of pregnant females with elective terminations
Number of pregnant females with elective terminations reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of fetal deaths/stillbirths
Number of fetal deaths/stillbirths reported in medical record
Time frame: From 20 weeks to study completion
Number of premature live births (<37 weeks)
Number of premature live births (\<37 weeks) reported in medical record
Time frame: Up to 37 weeks
Number pregnant females with with live term births
Number pregnant females with with live term births reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with normal vaginal delivery or C-section
Number of pregnant females with normal vaginal delivery or C-section reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of newborns with low birth weight (<2500 grams)
Number of newborns with low birth weight (\<2500 grams)
Time frame: At birth
Number of newborns with heart and circulation defects
Number of newborns with heart and circulation defects reported in medical record
Time frame: At birth
Number of newborns with genital and urinary tract defects
Number of newborns with genital and urinary tract defects reported in medical record
Time frame: At birth
Number of newborns with nervous system and eye defects
Number of newborns with nervous system and eye defects reported in medical record
Time frame: At birth
Number of newborns with Club foot
Number of newborns with Club foot reported in medical record
Time frame: At birth
Neonate mean body weight (kg)
Neonate mean body weight (kg)
Time frame: 1 month
Infant mean body weight (kg)
Infant mean body weight (kg)
Time frame: 12 months
Number of infants who sit unattended or without support
Number of infants who sit unattended or without support from medical record
Time frame: 12 months
Number of infants who pick up small objects with thumb-finger grasp
Number of infants who pick up small objects with thumb-finger grasp from medical record
Time frame: 12 months
Number of infants who say "Dada" or "Mama" nonspecifically
Number of infants who say "Dada" or "Mama" nonspecifically from medical record
Time frame: 12 months
Number of infants who look for dropped objects or objects hidden by parents
Number of infants who look for dropped objects or objects hidden by parents from medical record
Time frame: 12 months
Neonate mean body length (cm)
Neonate mean body length (cm)
Time frame: 1 month
Neonate mean head circumference (cm)
Neonate mean head circumference (cm)
Time frame: 1 month
Infant mean recumbent weight (kg)
Infant mean recumbent weight (kg)
Time frame: 12 months
Infant mean weight-for-length ratio (kg/cm)
Infant mean weight (kg) divided by body length (cm)
Time frame: 12 months